CONTENTS

PREFACE ix
CONTRIBUTORS xi

PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES 1

1. The Drug Discovery Process 3
   Gerald T. Miwa

2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors 15
   Geraldine Harriman, Amy Elder, and Indranath Ghosh

3. Bioanalytical Technologies in Drug Discovery 43
   Jing-Tao Wu

4. Safety Biomarkers in Drug Development: Emerging Trends and Implications 71
   Eric R. Fedyk

5. The Role of Drug Metabolism in Drug Discovery 91
   Tonika Bohnert and Liang-Shang Gan
6. Applied Pharmacokinetics in Drug Discovery and Development 177
   Hua Yang, Xingrong Liu, Anjaneya Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu

PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES—THE UNDESIRABLE INHIBITION 241

7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes 243
   R. Scott Obach

8. Cytochrome P450 Induction 265
   Edward L. LeCluyse, Michael W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi

   Aleksandra Galetin and J. Brian Houston

10. Enzyme Inhibition in Various In Vitro Systems 345
    Ping Zhao

11. Cytochrome P450 Degradation and Its Clinical Relevance 363
    Mingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia

12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition 407
    Michael B. Fisher

13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes 423
    Albert P. Li and Chuang Lu

14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors 443
    Suresh K. Balani
15. Transporter–Xenobiotic Interactions: An Important Aspect of Drug Development Studies 467
   Gang Luo, Richard Ridgewell, and Thomas Guenthner

16. Polymorphisms of Drug Transporters and Their Clinical Implications 503
   Cindy Q. Xia and Johnny J. Yang

17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation 533
   Lisa L. von Moltke and David J. Greenblatt

   Amin Rostami-Hodjegan

PART III. INHIBITION OF THE DRUG TARGET ENZYMES—THE DESIRABLE INHIBITION 569

19. NF-κB: Mechanism, Tumor Biology, and Inhibitors 571
   Lenny Dang

20. G-Protein-Coupled Receptors as Drug Targets 625
   Wenyan Miao and Lijun Wu

21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain 669
   Yi Liu and Ning Qin

22. Targeting the mTOR Pathway for Tumor Therapeutics 719
   Wei Chen

23. HIV-1 Protease Inhibitors as Antiretroviral Agents 749
   Sergei V. Gulnik, Elena Afonina, and Michael Eissenstat

INDEX 811